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This study aimed to demonstrate the state of modern practice with regard to 
renal cell carcinoma (RCC) outcomes and to assess the impacts of clinical 
and pathological factors such as histological subtype (HS) or nuclear grade 
on survival using a central pathological review based on current the World 
Health Organization classification and American Joint Committee on 
Cancer/Union for International Cancer Control staging system. 
 
Methods 
We collected glass slides and clinical data sets from 914 cases of RCC treated 
with curative nephrectomy from 1995 to 2000. Overall (OS), cancer-specific 
(CSS), and relapse-free survival (RFS) were compared with HS and nuclear 
grades determined by a central pathology review board comprising 5 





The 5- and 7-year CSS in the present study were 96% and 93%, respectively, 
and were superior to those reported in Western countries. The concordance 
rates between the original and reviewed HS and nuclear grades were 90.9 % 
and 21.1 %, respectively. HS correlated with OS (P = 0.043) but was not an 
independent prognostic factor in the multivariate analysis (P = 0.820).  
Tumor size, Fuhrman grade and infiltration type were common independent 
prognostic factors of OS, CSS, and RFS. 
 
Conclusions 
The current study represents the state of RCC outcomes in the era of 
cytokine treatment for metastasis. Central pathological review is an 
essential component of a multicenter study with long-term follow-up. Tumor 
size, Fuhrman grade, and infiltration type had much greater impacts on 
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The incidence of renal cell carcinoma (RCC) is increasing; RCC accounts for 
approximately 3% of all cancers among adults in Western countries, and its 
incidence is also increasing in Japan [1]. Although tumor staging (TNM), 
Fuhrman grade, and performance status (PS) are the most widely recognized 
prognostic factors for RCC, easily available prognostic parameters that 
facilitate patient management based on different mortality risks have been 
investigated [2]. Consequently, various nomograms and scoring algorithms 
have been proposed, although in most series data were collected over more 
than a decade without sufficient follow-up. In addition, few studies have 
included a central pathological review based on the current World Health 
Organization (WHO) classification (2004) [3] and the seventh edition of the 
American Joint Committee on Cancer (AJCC)/Union for International 
Cancer Control (UICC) staging system, which was published in 2009[4]. 
Therefore, information from those earlier studies cannot be applied to 
current patient management. Also, it remains uncertain whether the 
histological subtype (HS) is an independent prognostic factor for RCC. To the 
best of our knowledge, only 5 studies have investigated the prognostic impact 
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of HS through pathological review [5-9], and single pathologists performed 
pathological reviews in 4 of these studies. Furthermore, to demonstrate the 
state of modern practice with regard to RCC outcomes, a multi-institutional 
study of patient data collected during a short period is mandatory.  
Therefore, in this study we attempted to collect data from 914 cases of RCC 
treated with potentially curative nephrectomy at 22 centers during a short 
period (6 years) and investigated the impacts of anatomical and clinical 
factors, HS, and nuclear grades on survival using a central pathological 
review by 5 board-certified pathologists who specialized in renal neoplasm.  
 
Patients and Methods  
Patients  
We collected data from patients with histopathological diagnoses of RCC 
during original pathological evaluations at 22 urological centers in Japan 
between 1995 and 2000. To determine the exact situation regarding the 
outcomes of patients with RCC in 2000, we limited the data collection period 
to a relatively short duration of 6 years. The patients’ clinical records were 
extracted from each institutional database. Each center was requested to 
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conduct a follow-up mail or telephone survey to obtain survival data for more 
than 85% of patients with RCC at 5 years post-diagnosis. Collected data 
included the TNM stage (AJCC/UICC, seventh edition), original 
histopathological diagnosis made at each institution, PS, overall survival 
(OS), cancer-specific survival (CSS), relapse-free survival (RFS), clinical 
symptoms, and laboratory test results. Data were labeled at the respective 
institutions and pooled into a single database.  
 
Pathological evaluation 
To evaluate case eligibility for this study, 2 representative 
hematoxylin and eosin (H&E) slides from each case were requested for a 
central pathological review. The review board comprised 5 board-certified 
diagnostic pathologists specializing in urologic pathology, including 1 author 
(YM). Each pathologist assigned their interpretations according to the 
Heidelberg classification of renal cell carcinoma (UICC Workshop 1997) [10], 
the WHO classification (2004), and nuclear grade according to the Fuhrman 
system and Japanese classification [11]. In addition, papillary subtype was 
divided into 2 categories, types 1 and 2 papillary RCC. Cases with discordant 
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interpretations were reevaluated to obtain consensus on the HS and grade 
through pathology review committee meetings. The presence of coagulative 
tumor necrosis could not be evaluated because only 2 representative slides 
were available for review. 
 
Statistical analysis 
OS, CSS, and RFS curves were calculated according to the 
Kaplan–Meier method. The log-rank test was used to evaluate the effects of 
patients’ characteristics on OS, CSS, and RFS. To identify independent 
prognostic factors, we performed a Cox proportional hazards regression 
analysis with a backward elimination. A kappa statistic was used to measure 
the agreement between the initial diagnosis and central pathology review. 
All statistical analyses were conducted using SAS, version 9.2 (SAS Institute 




Patient population  
    A total of 914 cases of RCC treated with potentially curative 
nephrectomy (788 radical and 126 partial) against local tumors were 
collected; of these, 119 patients (13.0%) developed recurrent disease. The 
median follow-up period for the 782 surviving patients was 89 months, and 
the median survival duration was 47 months for the 132 patients who died 
during follow-up. Five cases (0.48%) died within 1 month of nephrectomy as 
a result of complications or rapid RCC progression in advanced cases, and 27 
cases (6.3%) of pT1a, cN0M0 RCC (n = 431) recurred after curative 
nephrectomy.  
 
Central pathology review 
  Of the 914 RCC cases diagnosed according to an original 
histopathological evaluation at each institution, 678 were classified as clear 
cell, 3 as multilocular clear, 49 as papillary, 51 as chromophobe, 1 as 
collecting ducts of Bellini, 1 as mucinous tubular and spindle, 24 as 
unclassified, 8 as other malignancy, 2 as oncocytoma, 3 as other benign, and 
94 as undetermined according to the WHO classification (2004) through a 
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central pathology review. In 814 of the 914 RCC cases, RCC diagnosis was 
confirmed through a central pathological review, and clinical data were 
available. The patient and tumor characteristics are summarized in Table 1. 
Diagnoses made by the review board included clear cell RCC in 681 cases 
(83.7%), papillary RCC in 49 (6.0%; type 1 = 14, type 2 = 35), chromophobe 
RCC in 51 (6.3%), and unclassified RCC in 33 (4.1%) according to the 
Heidelberg RCC classification. Discordance of HS according to the 
Heidelberg RCC classification was identified in 66 of 729 cases with 
available original diagnoses (concordance rate 90.9 %; kappa = 0.555; 95% 
confidence interval (CI) 0.465–0.654; Table 2A). Twenty-three cases 
diagnosed as chromophobe RCC by central pathology review had originally 
been diagnosed as clear cell RCC. Considerable discordance in the nuclear 
grade following Japanese classification was identified in 569 of 721 cases 
with available original diagnoses (concordance rate 21.1%; kappa = -0.079; 
95% CI -0.108–0.051; Table 2B). Two hundred and fifty-three and 100 cases 
diagnosed as G2 and G3 RCC by central pathology review had been 
originally diagnosed as G1. The overall concordance rate did not significantly 
differ among the institutions (P = 0.292).  
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HS and survival of RCC patients after potentially curative nephrectomy for 
local tumors 
The 5- and 7-year OS rates of 814 RCC cases treated with curative 
nephrectomy were 92% and 87%, respectively (Fig. 1A), and the 
corresponding CSS and RFS rates were 96% and 93% and 88% and 85%, 
respectively (Fig. 1B and 1C). A total of 110 cases (93 clear, 6 papillary, 6 
chromophobe, and 5 unclassified) from among 814 cases treated with 
curative nephrectomy experienced relapse during the follow-up period after 
curative nephrectomy. The 5-year CSS and RFS rates after curative 
nephrectomy among pT1N0M0, pT2N0M0, and pT3N0M0 cases in the 
present study were 99% and 96%, 93% and 80%, and 89% and 71%, 
respectively. Two hundred seventy-six cases received interferon-α as an 
adjuvant therapy. Interferon-α did not improve the OS (hazard ratio [HR] = 
1.199; 95% CI, 0.839–1.714; P = 0.319), CSS (HR = 2.333; 95% CI, 
1.405–3.874; P = 0.001), or RFS (HR = 2.428; 95% CI, 1.711–3.444; P <0.001) 
in the present study. 
In a univariate analysis, OS was associated with HS in 5 subtypes: clear, 
papillary type 1, papillary type 2, chromophobe, and unclassified (P = 0.043) 
(Fig. 2A and Table 3); however, no association was found with the clear and 
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non-clear subtypes (P = 0.170, Fig. 2B). The lowest HR relative to the clear 
subtype was observed for chromophobe (0.62), followed by papillary type１
(0.97), papillary type 2 (1.966), and unclassified subtype (2.426; Table 3).   
OS was also associated with tumor size (P <0.001; Fig. 2C and Table 3), 
Fuhrman grade (P <0.001), gender (P = 0.005), PS (P <0.001), TNM stage (P 
<0.001), preoperative hemoglobin (Hb) level (P = 0.004), platelet (Plt) count 
(P = 0.003), albumin (alb) level (P <0.001), and C-reactive protein (CRP) 
level (P = 0.014), whereas CSS and RFS did not associate with age, PS, Hb, 
alb, or Plt (data not shown). The Fuhrman grade was a good prognostic 
factor for the clear (P <0.0001) and papillary histologic subtypes (P = 
0.0389) but not the chromophobe subtype (P = 0.691), as previously 
described [12]. 
Additionally, we performed a multivariate analysis to identify the 
prognostic factors associated with OS, CSS, and RFS in RCC patients after 
potentially curative nephrectomy (Table 3). Hb, Plt, alb, and CRP were only 
available for approximately half of the patients and were therefore not 
included in this analysis. The multivariate analysis indicated that only 
tumor size, Fuhrman grade, and infiltration type were common independent 
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prognostic factors for OS, CSS, and RFS. Although gender was not directly 
related to age, female gender was a significantly good prognostic factor for 
OS (P <0.001) but not for RFS (P = 0.080).  
 
Discussion 
We collected clinical data from 914 RCC patients treated with curative 
nephrectomy over a 6-year period beginning in 1995 and analyzed both 
clinical and histological data. The histological findings of these cases were 
reevaluated by 5 pathologists. Most previous large outcome studies required 
a study period longer than a decade or international collaborations between 
institutions with various backgrounds to collect sufficient numbers of 
patients.  In contrast, the results from the current study appear to 
represent the true state of the art for RCC management during the era of the 
cytokine treatment for metastatic RCC (mRCC; circa 2000) in Japan.  
  The CSS rate in the present study appeared superior to those reported 
in Western countries, whereas the RFS rates were similar [13-16]. Fujii et al. 
also reported that the CSS among Japanese patients with RCC was longer 
than that reported in Western countries for patients with identical Mayo 
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Clinic stages, tumor sizes and grades, and necrosis (SSIGN) scores [17]. 
Naito et al. recently reported prolonged survival among mRCC patients in 
Japan when compared with those in Western countries during the era of 
cytokine treatment, suggesting that the lead time bias as a result of full 
medical tests and treatment coverage for all patients through the Japanese 
medical insurance system, genetic differences, or the use of non-recombinant 
interferon as an immunotherapy might have led to better prognoses [18]. 
Therefore, the long CSS in the present study might be the result of long 
survival of patients with metastatic RCC. 
Several studies have reported better survival among female patients 
than among male patients after curative nephrectomy [19, 20]. In the 
present study, significantly better survival was observed among female 
patients with regard to OS but not RFS. A survival analysis adjusted for the 
estimated life expectancy would be necessary to understand the differences 
in RCC biological behavior between the genders.   
The survival of RCC patients after curative nephrectomy did not 
significantly differ among the institutions after adjusting for gender, age, 
and tumor size (P = 0.082) and did not depend on the volumes of the 
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institutions. This is likely because most Japanese urologists (both residents 
in training and specialized urologists) experience multiple transitions 
between institutions, thus allowing the rapid transmission of surgical skills 
to all institutions, and because Japanese public medical insurance provides 
equal coverage to all hospitals in Japan. 
Data for laparoscopic nephrectomy were limited and only available in 50 
cases. This limitation reflects the policy of the Japanese public medical 
insurance system, which did not cover laparoscopic nephrectomy before 2002. 
However, local control of RCC via laparoscopic nephrectomy is comparable to 
that achieved via open nephrectomy [21] and is thus considered to be a 
reasonable method. Therefore, the results of the present study can be applied 
to localized RCC patients in current and future clinical settings. 
Although Ficarra et al. reported a recent improvement in the 
concordance between the original and reviewing pathologists regarding RCC 
HS (kappa = 0.43 from 1986 to 1997; 0.73 from 1998 to 2000) [5], 
considerable discordance was identified in the present study with regard to 
HS (9.1%) and nuclear grade (78.9%). These increased discordance rates 
highlight the importance of a central pathological review, particularly for 
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series that include cases from more than a decade ago.    
The prognostic significance of HS after curative nephrectomy was 
defined through univariate analysis [6-9, 22, 23]. Judging from the results 
of the present univariate analysis, patients with the chromophobe subtype 
had the best survival, followed by those with clear, papillary type 2, and 
unclassified subtypes; survival of papillary type 1 was almost equal to that 
of the clear subtype. However, whether HS is an independent prognostic 
factor remains under discussion. Leibovich et al. reported that HS was an 
independent predictor of outcome in a multivariate analysis of 3062 RCC 
patients from whom samples were collected between 1970 and 2003; in that 
study, all specimens were reviewed by a single pathologist [8]. Patard et al. 
reported that HS was not an independent prognostic factor in a 
multivariate analysis of 4204 RCC patients diagnosed between 1984 and 
2001, but those authors described the lack of a central pathological review 
as the main limitation of their study [22]. Although Capitaneo et al. 
reported that HS was an independent predictor of cancer-specific mortality 
(P = 0.03), those authors found no improvement in accuracy when HS was 
added to other predictors [23]. Ficarra et al. reported that HS was not an 
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independent predictor of outcome in a multivariate analysis of 491 RCC 
patients from whom data were collected between 1986 and 2000, in which 
all specimens were reassigned by a single pathologist [5]. Amin et al. 
concluded that HS was not an independent predictor of outcome in a 
multivariate analysis of 405 RCC patients collected between 1968 and 1994, 
in which the final pathological review was performed by 3 pathologists [6]. 
Crepel et al. recently reported that HS was not a prognostic factor for the 
use of partial nephrectomy to treat small RCC [24]. Furthermore, even the 
unclassified subtype was not proven to be a statistically independent 
survival factor [25].  Although Keegan et al. reported that the HS was 
predictive of survival, only the rare collecting duct and sarcomatoid HS of 
RCC were definite independent survival factors [26]. The merit of the 
current study is the employment of a central pathological review according 
to the current WHO classification and the inclusion of RCC patients 
diagnosed between 1995 and 2000 with sufficient follow-up, indicating that 
it is among the most reliable RCC outcome studies in the era of cytokine 
treatment. In a multivariate analysis of the associations with OS, CSS, and 
RFS after potentially curative nephrectomy against local RCC in the 
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present study, HS was not found to be an independent prognostic factor 
even after the papillary subtype was further classified as type 1 or 2; 
additionally, a survival analysis of rare HS such as collecting duct 
carcinoma or sarcomatoid RCC was impossible because of the limited 
sample size. In contrast, tumor size, Fuhrman grade (excluding cases with 
the chromophobe subtype), and infiltration type had a much greater impact 
on survival after curative nephrectomy in the present study. 
Certain potential limitations of the present study need to be considered. 
Despite analyzing a total of 814 RCC patients with available clinical and 
pathological evaluation data, the sample size was apparently not sufficiently 
large to determine statistical differences in survival among patients with 
different HS, including collecting duct HS and sarcomatoid HS. Moreover, 
although patients with RCC were consecutively enrolled in a retrospective 
manner, confirmation of the histopathological diagnosis of RCC in this study 
might have favored the selection of patients with resectable tumors. 
Therefore, a potential selection bias might have existed against patients 
with late-stage and rapidly growing disease. Finally, although central 
pathological reviews were performed by 5 specialized pathologists, only 2 
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representative H&E slides were available per case, resulting in 94 
undetermined HS cases. 
Despite some limitations, this report represents the true state of RCC 
outcomes via central pathological review near the year 2000. Although the 
RCC HS does not appear to be an independent prognostic factor after 
potentially curative nephrectomy, the prognostic significance of HS might 
increase after the emergence of targeting agents such as tyrosine-kinase 
inhibitors or mTOR inhibitors because some of these agents are designed to 
block the carcinogenic signaling pathways of specific RCC HS and therefore 
are more effective for these specific HS. It will be interesting to compare the 
significance of HS on RCC outcomes in the era of targeting agents with the 
present results.  
In conclusion, the present study reported some of the most updated 
and reliable data regarding the survival of RCC patients treated with 
curative nephrectomy. HS was not an independent prognostic factor of RCC, 
whereas tumor size, Fuhrman grade (excluding chromophobe subtype cases), 
and infiltration type had much greater impacts on survival in the era of 
cytokine treatment. Considerable discordance between the original and 
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centrally reviewed pathological results regarding the HS and nuclear grades  
indicated that a central pathological review conducted by experienced 
pathologists in accordance with updated histopathological classifications is 
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1. Overall survival (a), cancer-specific survival (b) and relapse-free survival 
(c) of 814 patients subjected to curative nephrectomy and central 
pathological diagnosis. 
2. Overall survival stratification according to the 5 histologic subtypes (clear, 
papillary type 1, papillary type 2, chromophobe, and unclassified) (a), 
clear vs. non-clear subtypes (b), and tumor size (c) among 814 patients 










Characteristic Clear Cell Papillary(Type 1)
Papillary
(Type 2) Chromophobe Unclassified P
*
Patients 681 (83.7) 14 (1.7) 35 (4.3) 51 (6.3) 33(4.1)
Gender
M 496 (72.8) 12 (85.7) 30 (85.7) 25 (49.0) 19 (57.6) 0.0003
F 185 (27.2) 2 (14.3) 5 (14.3) 26 (51.0) 14(42.4)
Age (years)
Mean ± SD 60.9 ± 11.3 65.1 ± 10.4 65.6 ± 9.7 60 ± 10.5 61.9± 12.8 0.082
Performance Status
0 491 (89.1) 11 (84.6) 28 (87.5) 40 (93.0) 23 (85.2) 0.835
1–4 60 (10.9) 2 (15.4) 4 (12.5) 3 (7.0) 4 (14.8)
BMI 
Mean ± SD 23.2 ± 3.3 21.8 ± 2.0 22.5± 3.2 23.9 ± 3.2 22.1 ± 3.6 0.067
Clinical presentation
Incidental 508 (74.9) 11 (78.6) 24 (68.6) 36 (70.6) 19 (59.4) 0.306
Symptomatic 170 (25.1) 3 (21.4) 11 (31.4) 15 (29.4) 13 (40.6)
Tumor size (cm)
Mean ± SD 4.8 ± 2.7 5.3± 2.3 4.3 ± 2.7 5.5 ± 3 4.9 ± 1.9 0.273
T stage
1a/1b/2a/2b 580 (88.8) 13 (92.9) 28 (82.4) 45 (95.7) 26 (83.9) 0.320
3a/3b/3c/4 73 (11.2) 1 (7.1) 6 (17.6) 2 (4.3) 5 (16.1)
Hb (g/dL)
Mean ± SD 13.5 ± 1.9 13.5 ± 1.3 13.1 ± 2.0 13.4 ± 1.8 12.0 ± 2.2 0.0005
Plt (104/mm3)
Mean ± SD 25.7± 22.4 22.4 + 6.1 24.4 ± 9.5 22.9 ± 6.9 26.7 ± 8.7 0.878
LDH (IU/L)
Mean ± SD 271.5 ± 105.3 371.3± 309.8 296.5 ± 135 351 ± 108 282.2 ± 117.6 0.0001
Alb (g/dL)
Mean ± SD 4.2 ± 0.6 4.2 ± 0.7  4.0 ± 0.4 4.2 ± 0.8 4.1  ± 0.7 0.583
Corrected Ca (mg/dL)
Mean ± SD 8.1 ± 2.3 8.9 ± 0.4 8.5 ± 1.8 8.9 ± 2.2 7.5 ± 2.7 0.096
CRP (mg/dL)
Mean ± SD 1.0 ± 3.0 0.2 ± 0.1 2.3 ± 4.7 0.6 ± 2.1 1.8 ± 3.2 0.165
Infiltration
INF α 399 (81.4) 8 (80.0) 19 (70.4) 31 (79.5) 18 (64.3) 0.164
INF β/INF γ 91 (18.6) 2 (20.0) 8 (29.6) 8 (20.5) 10 (35.7)
Venous invasion
v(-) 393 (77.8) 9 (81.8) 17 (70.8) 31 (88.6) 19 (70.4) 0.406
v(+) 112 (22.2) 2 (18.2) 7 (29.2) 4 (11.4) 8 (29.6)
Fuhrman grade
G1/G2 436 (64.0) 10 (71.4) 13 (37.1) 9 (17.6) 6 (24.0) 0.0001
G3/G4 245 (36.0) 4 (28.6) 22 (62.9) 42 (82.4) 19 (76.0)
* Chi-squared test for categorical variables and ANOVA for continuous variables.
Descriptive characteristics of 814 renal cell carcinoma (RCC) patients with curative nephrectomy for whom both
clinical data and a central pathological review were available, stratified by histological subtype (HS) according to the
Heidelberg Classification and the descriptions of types 1 and 2 papillary RCC (percentages in parentheses)
SD, standard deviation; BMI, body mass index; Hb, hemoglobin; Plt, platelet count; LDH, lactate dehydrogenase; Alb,
albumin; Ca, calcium; CRP, C-reactive protein; INF, infiltration
Table 2
A
clear papillary chromophobe unclassified
Original histological subtype
clear 620 5 23 13
papillary 10 31 0 6
chromophobe 1 0 11 0




G1 6 253 100
G2 4 125 211
G3 0 1 21
Concordance rate = 21.1%; kappa = -0.079; 95% confidence interval (CI), -0.108–0.051
Central pathology review
Concordance of histological subtypes (a) and nuclear grade (b) between original and centrally
reviewed pathology results
Concordance rate = 90.9%; kappa = 0.555; 95% confidence interval (CI), 0.465–0.654
Central pathology review
Table 3
Univariate and multivariate analyses of prognostic factors for survival after curative nephrectomy
CSS RFS
Multivariate Multivariate Multivariate
HR 95% CI P P* P* P* P*
Gender M 1 0.005 <0.001 0.048 0.069
F 0.500 0.309–0.811 0.005
Age 1.045 1.025–1.064 <0.001 <0.001 <0.001 0.391 0.097
Hemodialysis  - 1 <0.001 <0.001 0.061 0.638
 + 5.434 1.998–14.78 <0.001
Performance status 0 1 － － <0.001 <0.001 0.903 0.486
1 3.045 1.805–5.138 <0.001
2–4 7.161 2.868–17.88 <0.001
Tumor size 1.162 1.105–1.221 <0.001 <0.001 <0.001 <0.001 <0.001
T stage 1a 1 <0.001 0.305 0.015 0.001
1b 1.325 0.760–2.309 0.321
2 2.215 1.143–4.291 0.018
3a 2.454 1.350–4.462 0.003
3b 4.503 2.474–8.99 <0.001
3c 9.901 3.026–32.40 <0.001
4 14.17 1.903–105.5 0.010
Infiltration type INF α 1 <0.001 0.016 0.001 <0.001
INF β 2.167 1.362–3.448 0.001
INF γ 13.06 4.059–42.02 <0.001
Venous invasion  - 1 <0.001 0.232 0.335 0.777
 + 3.087 2.037–4.680 <0.001
Fuhrman grade  1/2 1 <0.001 0.005 <0.001 0.002
3 2.470 1.640–3.720 <0.001
4 2.236 1.305-3.830 0.003
Histological subtype clear 1 0.043 0.714 0.499 0.999
papillary type 1 0.970 0.239–3.937 0.966
papillary type 2 1.966 0.954–4.051 0.067
chromophobe 0.620 0.228–1.686 0.349
unclassified 2.426 1.177–5.000 0.016
* Global association
OS, overall survival; CSS, cancer-specific survival; RFS, relapse-free survival; HR, hazard ratio; CI, confidence interval; INF, infiltration
Univariate
OS
